Tag Archive | "licensing"

Boehringer Ingelheim and Oxford BioTherapeutics in oncology pact

Tags: , , ,


Oxford BioTherapeutics announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to an oncology target from an ongoing discovery collaboration Read the full story

Janssen and AC Immune partner for ACI-35

Tags: , , , ,


AC Immune has entered into a worldwide exclusive license agreement and research collaboration with Janssen Pharmaceuticals Read the full story

Janssen licenses Tipifarnib to EB Pharma

Tags: , , ,


EB Pharma has executed an agreement with Janssen Pharmaceutica for an exclusive license, to tipifarnib in the field of virology and a related, clinical stage back-up compound Read the full story

Modern Biosciences and Janssen Biotech partner for novel bone-protective compounds for RA

Tags: , , , ,


Modern Biosciences has entered into an R&D alliance and global option and licence agreement with Janssen Biotech in relation to MBS’ novel bone-protective compounds for the treatment of rheumatoid arthritis Read the full story

Mylan and Gilead in tenofovir alafenamide licensing pact

Tags: , , , , ,


Mylan has entered into an agreement with Gilead Sciences under which Mylan has licensed the non-exclusive rights to manufacture and distribute Tenofovir Alafenamide Read the full story

Editas scoops CRISPR/Cas9 and TALE genome editing technologies from 4 academics groups

Tags: , ,


Editas Medicine have entered into a series of license agreements to access intellectual property and technology related to the CRISPR/Cas9 and TALENs genome editing systems Read the full story

Camurus and Braeburn Pharmaceuticals enter exclusive license agreement

Tags: , ,


Camurus and Braeburn Pharmaceuticals have entered into an exclusive license agreement for Camurus’ weekly and monthly subcutaneous buprenorphine injection products (CAM2038) for the treatment of opioid addiction and pain. Read the full story

Presidio commences out-licensing PPI-668

Tags: ,


Pharco and Presidio have entered into an exclusive license agreement for Presidio’s HCV NS5A inhibitor PPI-668 for development and commercialization to treat HCV infection Read the full story

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics

Tags: , , ,


The Licensing Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

 

The report provides a detailed understand and analysis of how and why companies enter licensing deals.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

 

This report contains links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by biopharma companies and their partners.

 

Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of licensing dealmaking and business activities.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in licensing as well as a discussion on the merits of the type of deal.

 

Chapter 3 provides an overview of the structure of licensing deals. The chapter includes numerous case studies to enable understanding of both pure licensing deals and multicomponent deals where licensing forms a part.

 

Chapter 4 provides a review of the leading licensing deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, signed by bigbiotech, most active bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

 

Chapter 5 provides a comprehensive review of licensing financials for deals announced since 2009, including headline value, upfront, milestone payments and royalty rates by stage of development, providing both benchmark data and access to individual deal financials.

 

Chapters 6 and 7 provide a comprehensive listing of the top 50 bigpharma and bigbiotech companies with a brief summary followed by a comprehensive listing of licensing deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 8 provides a comprehensive and detailed review of licensing deals signed and announced since 2009 where a contract document is available. The chapter is organized by company A-Z, stage of development at signing, technologyand therapeutic area. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

The report also includes numerous table and figures that illustrate the trends and activities in licensing dealmaking since 2009.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about licensing dealmaking, enabling thorough learning, education and due diligence prior and during the licensing dealmaking process.

 

Report scope

 

Licensing Terms and Agreements in Pharma, Biotech and Diagnostics is intended to provide the reader with an in-depth understanding of the licensing trends and structure of deals entered into by leading life science companies worldwide.

 

Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics includes:

 

  • Trends in licensing dealmaking in the biopharma industry since 2009
  • Analysis of licensing deal structure
  • Case studies of real-life licensing deals
  • Comprehensive listing of licensing deals since 2009
  • Access to licensing contract documents
  • Key financial bnchmarks for headline, upfront, milestone and royalty rates
  • The leading licensing deals by value since 2009
  • Most active licensing dealmakers since 2009
  • The leading licensing partnering resources

In Licensing Terms and Agreements in Pharma, Biotech and Diagnostics available deals and contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

 

Each deal title links via Weblink to an online version of the actual deal record and where available, contract document, providing easy access to each contract document on demand.

Read the full story

Top 50 Big Pharma Partnering and M&A Deal Trends

Tags: , , , , ,


The Top 50 Big Pharma Partnering and M&A Deal Trends report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies. Read the full story